Dexlansoprazole Patent Expiration
Dexlansoprazole is Used for treating gastroesophageal reflux disease (GERD) and maintaining the healing of erosive esophagitis. It was first introduced by Takeda Pharmaceuticals Usa Inc
Dexlansoprazole Patents
Given below is the list of patents protecting Dexlansoprazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Dexilant | US9233103 | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy | Mar 05, 2032 | Takeda Pharms Usa |
| Dexilant |
US8173158 (Pediatric) | Methods of treating gastrointestinal disorders independent of the intake of food | Sep 17, 2030 | Takeda Pharms Usa |
| Dexilant | US8173158 | Methods of treating gastrointestinal disorders independent of the intake of food | Mar 17, 2030 | Takeda Pharms Usa |
| Dexilant Solutab | US9241910 | Orally-disintegrating solid preparation | Mar 10, 2029 | Takeda Pharms Usa |
| Dexilant Solutab |
US8871273 (Pediatric) | Method for producing granules | Jul 11, 2028 | Takeda Pharms Usa |
| Dexilant | US8871273 | Method for producing granules | Jan 11, 2028 | Takeda Pharms Usa |
| Dexilant Solutab | US8871273 | Method for producing granules | Jan 11, 2028 | Takeda Pharms Usa |
| Dexilant |
US8105626 (Pediatric) | Granules containing acid-unstable chemical in large amount | Mar 27, 2027 | Takeda Pharms Usa |
| Dexilant |
US7790755 (Pediatric) | Controlled release preparation | Feb 02, 2027 | Takeda Pharms Usa |
| Dexilant | US8105626 | Granules containing acid-unstable chemical in large amount |
Sep 27, 2026
(Expired) | Takeda Pharms Usa |
| Dexilant | US7790755 | Controlled release preparation |
Aug 02, 2026
(Expired) | Takeda Pharms Usa |
| Dexilant |
US8461187 (Pediatric) | Multiple PPI dosage form |
Jul 17, 2026
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US8461187 (Pediatric) | Multiple PPI dosage form |
Jul 17, 2026
(Expired) | Takeda Pharms Usa |
| Dexilant | US9011926 | Method for producing granules |
Feb 24, 2026
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US9011926 | Method for producing granules |
Feb 24, 2026
(Expired) | Takeda Pharms Usa |
| Dexilant | US8461187 | Multiple PPI dosage form |
Jan 17, 2026
(Expired) | Takeda Pharms Usa |
| Dexilant | US9238029 | Multiple PPI dosage form |
Jan 17, 2026
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US8461187 | Multiple PPI dosage form |
Jan 17, 2026
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US9238029 | Multiple PPI dosage form |
Jan 17, 2026
(Expired) | Takeda Pharms Usa |
| Dexilant |
US8722084 (Pediatric) | Controlled release preparation |
Apr 15, 2024
(Expired) | Takeda Pharms Usa |
| Dexilant |
US8784885 (Pediatric) | Controlled release preparation |
Apr 15, 2024
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US8784885 (Pediatric) | Controlled release preparation |
Apr 15, 2024
(Expired) | Takeda Pharms Usa |
| Dexilant | US8722084 | Controlled release preparation |
Oct 15, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant | US8784885 | Controlled release preparation |
Oct 15, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US8784885 | Controlled release preparation |
Oct 15, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6664276 (Pediatric) | Benzimidazole compound crystal |
Jul 30, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6664276 | Benzimidazole compound crystal |
Jan 30, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant |
US6462058 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant |
US6664276 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant |
US6939971 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant |
US7285668 (Pediatric) | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6462058 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6939971 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7285668 (Pediatric) | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US6462058 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US6664276 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US6939971 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US7285668 | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US9145389 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6462058 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6939971 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7285668 | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US9145389 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6238994 (Pediatric) | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6328994 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7431942 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7875292 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6238994 | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6328994 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7431942 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7875292 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7399485 (Pediatric) | Rapidly Disintegrable solid preparation |
Nov 26, 2018
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7399485 | Rapidly Disintegrable solid preparation |
May 26, 2018
(Expired) | Takeda Pharms Usa |
Dexlansoprazole's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Dexlansoprazole:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old | Takeda | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old | Takeda | NA |
TERMINATED
(May 1, 2026)
| PHASE2 |